Today: 12 June 2026
Browse Category

LSE:D4D 10 September 2025

Engineered Living Therapeutics: How “Bugs as Drugs” Are Transforming Medicine in 2025

Engineered Living Therapeutics: How “Bugs as Drugs” Are Transforming Medicine in 2025

Regulators approved the first microbiome-based therapies for infection in 2022–2023, including Rebyota and Vowst. Next-generation engineered microbes are now in clinical trials for cancer, metabolic, and immune disorders. Synthetic biology advances enable microbes to sense and respond inside the body. Major biotech firms and pharma are investing, with positive Phase 3 results reported for some live microbe therapies in 2025.
10 September 2025
·

Stock Market Today

  • SharonAI Shares Surge on $4.88 Billion NVIDIA AI Cloud Deal
    June 12, 2026, 10:08 AM EDT. SharonAI's stock jumped to $71.51 following a six-year $4.88 billion collaboration with NVIDIA to build AI data-center capacity in Australia. The deal involves deploying up to 40,000 NVIDIA Grace Blackwell GB300 GPUs, expanding SharonAI's AI computing infrastructure to 132 megawatts. Although the company remains unprofitable and depends on future contract execution, the NVIDIA partnership strengthens its supply chain credibility amid strong demand for AI cloud capacity. Market value reached $998 million, highlighting investor focus on SharonAI's growth potential rather than current earnings. Major customer contracts worth over $2 billion also support the company's expansion plans but risks include financing and operational delivery challenges.

Latest articles

SharonAI Stock Jumps as Nvidia Deal Puts $4.88 Billion AI Cloud Bet in Focus

SharonAI Stock Jumps as Nvidia Deal Puts $4.88 Billion AI Cloud Bet in Focus

12 June 2026
SharonAI shares surged after announcing a six-year, $4.88 billion NVIDIA collaboration for up to 40,000 Grace Blackwell GPUs and 72MW of new AI data-center capacity in Australia, but the company remains unprofitable, faces key execution and financing risks, and analysts’ average price target of $65 is below the recent $71.51 quote.
T3 Defense Sees Stock Shift as CFO Starts Ahead of Nasdaq Vote

T3 Defense Sees Stock Shift as CFO Starts Ahead of Nasdaq Vote

12 June 2026
T3 Defense named Roy Cohen CFO just days before a crucial June 18 shareholder vote on major share issuances and a possible reverse stock split, as DFNS stock rebounded pre-market after closing Thursday at $0.2566, down 6.72%; the outcome could impact dilution risk and the company’s ability to meet Nasdaq’s $1 minimum bid requirement.
IREN Bounces After Needham Cuts Targets, Market Watches AI Cloud Moves

IREN Shares Bounce While Investors Assess AI Cloud Prospects, Ongoing Funding Concerns

12 June 2026
IREN surged $5.16 to $56.71 after a volatile week, as investors weighed Needham’s cut to 2026-27 estimates on delayed AI cloud revenue ramp, with mining revenue expected to approach zero by year-end as GPU deployments replace Bitcoin capacity; the next key catalyst is proof of billable AI cloud revenue ahead of the September 16 earnings update.
Go toTop